PURPOSE: Test pharmacokinetics and biodistribution of a human papillomavirus(HPV)16L1 DNA vaccine delivered in human endogenous retrovirus envelope protein (HERV)-expressing baculovirus (AcHERV) and those of naked plasmid vaccine. METHOD: HPV16L1 gene was administrated as a naked plasmid or in AcHERV to mice via intravenous and intramuscular routes. HPV16L1 gene was extracted and assayed by quantitative real-time polymerase chain reaction, which was determined to have a detection limit of 50 copies/µg genomic DNA.. RESULTS: Mean residence times of HPV16L1 in AcHERV were 4.8- and 272.2-fold higher than naked HPV16L1 DNA vaccines after intramuscular and intravenous administration, respectively. Naked HPV16L1 DNA levels 1 month after injection were >3 orders of magnitude lower in each tissue tested than AcHERV-delivered HPV16L1, which was retained in most tissues without specific tissue tropism. AcHERV-delivered HPV16L1 administered intramuscularly persisted at the injection sites. However, the levels of copy numbers in muscle were low (1,800/μg genomic DNA) after 1 month, and undetectable after 6 months. CONCLUSIONS: HPV16L1 delivered via AcHERV resides longer in the body than HPV16L1 in naked form. The lack of tissue tropism ensures the safety of AcHERV vectors for further development.
PURPOSE: Test pharmacokinetics and biodistribution of a human papillomavirus(HPV)16L1 DNA vaccine delivered in human endogenous retrovirus envelope protein (HERV)-expressing baculovirus (AcHERV) and those of naked plasmid vaccine. METHOD: HPV16L1 gene was administrated as a naked plasmid or in AcHERV to mice via intravenous and intramuscular routes. HPV16L1 gene was extracted and assayed by quantitative real-time polymerase chain reaction, which was determined to have a detection limit of 50 copies/µg genomic DNA.. RESULTS: Mean residence times of HPV16L1 in AcHERV were 4.8- and 272.2-fold higher than naked HPV16L1 DNA vaccines after intramuscular and intravenous administration, respectively. Naked HPV16L1 DNA levels 1 month after injection were >3 orders of magnitude lower in each tissue tested than AcHERV-delivered HPV16L1, which was retained in most tissues without specific tissue tropism. AcHERV-delivered HPV16L1 administered intramuscularly persisted at the injection sites. However, the levels of copy numbers in muscle were low (1,800/μg genomic DNA) after 1 month, and undetectable after 6 months. CONCLUSIONS: HPV16L1 delivered via AcHERV resides longer in the body than HPV16L1 in naked form. The lack of tissue tropism ensures the safety of AcHERV vectors for further development.
Authors: Rodolphe Gravier; Daniel Dory; Michel Laurentie; Stéphanie Bougeard; Roland Cariolet; André Jestin Journal: Vaccine Date: 2007-07-23 Impact factor: 3.641
Authors: B Romanowski; P Colares de Borba; P S Naud; C M Roteli-Martins; N S De Carvalho; J C Teixeira; F Aoki; B Ramjattan; R M Shier; R Somani; S Barbier; M M Blatter; C Chambers; D Ferris; S A Gall; F A Guerra; D M Harper; J A Hedrick; D C Henry; A P Korn; R Kroll; A-B Moscicki; W D Rosenfeld; B J Sullivan; C S Thoming; S K Tyring; C M Wheeler; G Dubin; A Schuind; T Zahaf; Mary Greenacre; An Sgriobhadair Journal: Lancet Date: 2009-12-12 Impact factor: 79.321
Authors: James J Yun; Lawrence E Heisler; Irene I L Hwang; Olivia Wilkins; Suzanne K Lau; Martin Hyrcza; Bamini Jayabalasingham; Jing Jin; JoAnne McLaurin; Ming-Sound Tsao; Sandy D Der Journal: Nucleic Acids Res Date: 2006-07-13 Impact factor: 16.971